inproquone (E39)

major descriptor (78-80); replaced major descriptor Bayer E39 (63-77); on-line search AZIRINES (66-80); Index Medicus search Bayer E39 (63-77), INPROQUONE (78-80)

Also Known As:

E39; Bayer E39; inprochon

Networked: 13 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azirines
    - Aziridines: 14
      - inproquone: 13

Experts

1.	Berry, John S: 1 article (01/2019)
2.	Brown, Tommy A: 1 article (01/2019)
3.	Byrd, Kevin: 1 article (01/2019)
4.	Clifton, Guy T: 1 article (01/2019)
5.	Conrads, Thomas P: 1 article (01/2019)
6.	Darcy, Kathleen M: 1 article (01/2019)
7.	Elkas, John C: 1 article (01/2019)
8.	Greene, Julia M: 1 article (01/2019)
9.	Hale, Diane F: 1 article (01/2019)
10.	Hamilton, Chad A: 1 article (01/2019)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2019 - "We conducted a phase I/IIa trial of the E39 + GM-CSF vaccine with booster inoculations of either E39 or E39' (an attenuated version of E39) to prevent recurrences in disease-free endometrial and ovarian cancer patients(pts). "
2.	Neoplasms (Cancer) 07/01/1957 - "[Action of E39 in malignant pharyngolaryngeal tumors]." 01/01/1960 - "[Electron microscopic studies on the effect of ethyleneiminoquinone (E39) and carcinophilin on ascites tumor cells. " 01/01/1999 - "An aqueous extract of the marine diatom Haslea ostrearia (Simonsen) was studied for its antiproliferative properties against human solid tumors: lung carcinoma (NSCLC-N6), kidney carcinoma (E39) and melanoma (M96). " 01/01/1999 - "Antitumor and antiproliferative effects of an aqueous extract from the marine diatom Haslea ostrearia (Simonsen) against solid tumors: lung carcinoma (NSCLC-N6), kidney carcinoma (E39) and melanoma (M96) cell lines." 12/01/1999 - "Both immunodominant E39 (FBP, 191-199) and subdominant E41 (FBP, 245-253) epitopes are presented by HLA-A2 in these cancers. "
3.	Endometrial Neoplasms (Endometrial Cancer) 01/01/2019 - "Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients."
4.	Ascites 01/01/1960 - "[Electron microscopic studies on the effect of ethyleneiminoquinone (E39) and carcinophilin on ascites tumor cells. "
5.	Dysphonia (Spastic Dysphonia) 01/01/2021 - "Retraction notice to "Outcome measurement in the treatment of spasmodic dysphonia: A systematic review of the literature" [Journal of Voice 33.5 (2019) 810.e13 - 810.e39] Anna Rumbach, Patrick Aiken, Daniel Novakovic."

Related Drugs and Biologics

1.	Vaccines
2.	Folic Acid (Vitamin M)
3.	Carrier Proteins (Binding Protein)
4.	Protein Subunit Vaccines
5.	Voriconazole (Vfend)
6.	Recoverin
7.	Itraconazole (Sporanox)
8.	Synaptophysin
9.	HLA-A2 Antigen (HLA A2 Antigen)
10.	Vimentin